Lenvatinib + Ifosfamide + Etoposide + Lenvatinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteosarcoma
Conditions
Osteosarcoma
Trial Timeline
Mar 23, 2020 → Aug 17, 2023
NCT ID
NCT04154189About Lenvatinib + Ifosfamide + Etoposide + Lenvatinib
Lenvatinib + Ifosfamide + Etoposide + Lenvatinib is a phase 2 stage product being developed by Eisai for Osteosarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04154189. Target conditions include Osteosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04154189 | Phase 2 | Completed |
Competing Products
18 competing products in Osteosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azenosertib + Gemcitabine | Zentalis Pharmaceuticals | Phase 1/2 | 33 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Olaparib + Ceralasertib | AstraZeneca | Phase 2 | 52 |
| Saracatinib + Placebo | AstraZeneca | Phase 2 | 52 |
| robatumumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| pazopanib | Novartis | Phase 2 | 52 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Nivolumab + Azacitidine | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cisplatin liposomal | Insmed | Phase 1/2 | 38 |
| Cabozantinib | Ipsen | Phase 2 | 49 |
| Sm-EDTMP | Jazz Pharmaceuticals | Phase 2 | 49 |
| LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Lantheus Holdings | Phase 1/2 | 38 |
| REOLYSIN® | Oncolytics Biotech | Phase 2 | 44 |